Active, not recruitingPhase 3NCT05175105
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Studying Disorder of glycolysis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Principal Investigator
- Medical AffairsAgios Pharmaceuticals, Inc.
- Intervention
- Mitapivat(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2022 – 2030
Study locations (19)
- Stanford Medicine, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Healthcare of Atlanta - Emory, Atlanta, Georgia, United States
- UChicago Medicine, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St Jude's Children's Research Hospital, Memphis, Tennessee, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- Centre hospitalier Universitaire de Sainte-Justine, Montreal, Quebec, Canada
- Hôpital Pellegrin, Bordeaux, Aquitaine, France
- Universitatsklinikum Wurzburg, Würzburg, Bavaria, Germany
- Charite - UB - CVK - Medizinische Klinik, Berlin, Germany
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05175105 on ClinicalTrials.govOther trials for Disorder of glycolysis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05144256A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNCT04902833Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsMassachusetts General Hospital
- ACTIVE NOT RECRUITINGNCT03481738Pyruvate Kinase Deficiency Global Longitudinal RegistryAgios Pharmaceuticals, Inc.